ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FARN Faron Pharmaceuticals Oy

137.50
-2.50 (-1.79%)
Last Updated: 14:16:06
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -1.79% 137.50 135.00 140.00 140.00 135.00 140.00 40,251 14:16:06
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -28.73M -0.4177 -3.29 94.58M

Faron Pharmaceuticals Oy Faron to Host KOL Webinar on Clever-1 Receptor

12/07/2021 7:00am

RNS Non-Regulatory


TIDMFARN

Faron Pharmaceuticals Oy

12 July 2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron to Host KOL Webinar on the Potential of Clever-1 Receptor as a Target for Macrophage-Guided Immunotherapy on July 19, 2021

TURKU, FINLAND / BOSTON, MA, July 12, 2021 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that it will host a webinar entitled 'Clever-1 as a target for macrophage-guided immunotherapy' on Monday 19 July 2021 at 8.30 am EDT, 13.30 pm BST, 15.30 pm EEST.

The webinar will feature a presentation by key opinion leader (KOL), Dr. Maija Hollmén, adjunct professor of tumour immunology, group leader and academy research fellow at the MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Finland. Additionally, Chief Executive Officer of Faron, Dr. Markku Jalkanen, will present on the potential of bexmarilimab, Faron's wholly-owned, novel precision cancer immunotherapy targeting Clever-1, which is currently in Phase I/II development as a potential monotherapy in patients with solid tumours who have exhausted all treatment options.

The presentation will be followed by a live Q&A session. The event can be accessed at the "Investors" section on Faron's website at https://www.faron.com/investors . A replay will be made available on the investor section of Faron's website shortly after the event.

Ends

For more information please contact:

Media Contact

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com

+1 (610) 529-6219

Investor Contact

Julie Seidel

julie.seidel@sternir.com

Phone: +1 (212) 362-1200

Peel Hunt LLP, Broker

Dr Christopher Golden, James Steel

Phone: + 44 (0)20 7418 8900

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner, Mark Rogers

Phone. +44 (0)20 7213 0880

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 55 38 990

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumours, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalised patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com .

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "expect", "hope", "seek", "envisage", "estimate", "intend", "may", "plan", "potentially", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADKDBPQBKDBOD

(END) Dow Jones Newswires

July 12, 2021 02:00 ET (06:00 GMT)

1 Year Faron Pharmaceuticals Oy Chart

1 Year Faron Pharmaceuticals Oy Chart

1 Month Faron Pharmaceuticals Oy Chart

1 Month Faron Pharmaceuticals Oy Chart

Your Recent History

Delayed Upgrade Clock